speb/financial-data huggingface dataset:
XBIO income_statement (annual, 2022-12-31) — Normalized EBITDA: -6690865.00
XBIO income_statement (annual, 2022-12-31) — Normalized Income: -6552353.00
XBIO cash_flow (annual, 2022-12-31) — Operating Cash Flow: -4646765.00
XBIO income_statement (annual, 2022-12-31) — Operating Income: -6717908.00
XBIO income_statement (annual, 2022-12-31) — Operating Revenue: 1706925.00
XBIO balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 1516659.00
XBIO balance_sheet (annual, 2022-12-31) — Other Current Assets: 556094.00
XBIO balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 39949.00
XBIO balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: 253734.00
XBIO income_statement (annual, 2022-12-31) — Other Gand A: 3653999.00
XBIO income_statement (annual, 2022-12-31) — Other Income Expense: -1597.00
XBIO cash_flow (annual, 2022-12-31) — Other Non Cash Items: 1793750.00
XBIO balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 1066931.00
XBIO income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: -1597.00
XBIO balance_sheet (annual, 2022-12-31) — Payables: 287360.00
XBIO balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 1033207.00
XBIO balance_sheet (annual, 2022-12-31) — Preferred Stock: 2774.00
XBIO balance_sheet (annual, 2022-12-31) — Preferred Stock Equity: 2774.00
XBIO balance_sheet (annual, 2022-12-31) — Prepaid Assets: 556094.00
XBIO income_statement (annual, 2022-12-31) — Pretax Income: -6552353.00
XBIO cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 0.00
XBIO cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -500000.00
XBIO income_statement (annual, 2022-12-31) — Reconciled Depreciation: 27043.00
XBIO income_statement (annual, 2022-12-31) — Research And Development: 4770834.00
XBIO balance_sheet (annual, 2022-12-31) — Retained Earnings: -189099618.00
XBIO income_statement (annual, 2022-12-31) — Selling General And Administration: 3653999.00
XBIO balance_sheet (annual, 2022-12-31) — Share Issued: 1519358.00
XBIO cash_flow (annual, 2022-12-31) — Stock Based Compensation: 511480.00
XBIO balance_sheet (annual, 2022-12-31) — Stockholders Equity: 13647134.00
XBIO balance_sheet (annual, 2022-12-31) — Tangible Book Value: 13644360.00
XBIO income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
XBIO income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
XBIO balance_sheet (annual, 2022-12-31) — Total Assets: 14720290.00
XBIO balance_sheet (annual, 2022-12-31) — Total Capitalization: 13647134.00
XBIO balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 13647134.00
XBIO income_statement (annual, 2022-12-31) — Total Expenses: 8424833.00
XBIO balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 1073156.00
XBIO balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 1066931.00
XBIO balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
XBIO income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -6717908.00
XBIO balance_sheet (annual, 2022-12-31) — Treasury Shares Number: 2699.00
XBIO balance_sheet (annual, 2022-12-31) — Treasury Stock: 5281180.00
XBIO balance_sheet (annual, 2022-12-31) — Working Capital: 12580203.00
XBIO income_statement (annual, 2023-12-31) — +Operating Expense: 7055701.00
XBIO income_statement (annual, 2023-12-31) — +Total Revenue: 2539986.00
XBIO balance_sheet (annual, 2023-12-31) — Accounts Payable: 240832.00
XBIO balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 208053935.00
XBIO income_statement (annual, 2023-12-31) — Basic Average Shares: 1528210.00
XBIO income_statement (annual, 2023-12-31) — Basic EPS: -2.71
XBIO cash_flow (annual, 2023-12-31) — Beginning Cash Position: 13097265.00
XBIO balance_sheet (annual, 2023-12-31) — Capital Stock: 3348.00
XBIO balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 8983046.00
XBIO balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 8983046.00
XBIO balance_sheet (annual, 2023-12-31) — Cash Financial: 8983046.00
XBIO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: 0.00
XBIO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -4114219.00
XBIO cash_flow (annual, 2023-12-31) — Change In Account Payable: -263571.00
XBIO cash_flow (annual, 2023-12-31) — Change In Other Current Assets: 48579.00
XBIO cash_flow (annual, 2023-12-31) — Change In Payable: -263571.00
XBIO cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: -263571.00
XBIO cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -47734.00
XBIO cash_flow (annual, 2023-12-31) — Change In Working Capital: -262726.00
XBIO cash_flow (annual, 2023-12-31) — Changes In Cash: -4114219.00
XBIO balance_sheet (annual, 2023-12-31) — Common Stock: 1544.00
XBIO balance_sheet (annual, 2023-12-31) — Common Stock Equity: 9793837.00
XBIO balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 520497.00
XBIO balance_sheet (annual, 2023-12-31) — Current Assets: 9586874.00
XBIO balance_sheet (annual, 2023-12-31) — Current Liabilities: 809585.00
XBIO cash_flow (annual, 2023-12-31) — Depreciation: 0.00
XBIO cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 0.00
XBIO cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 0.00
XBIO income_statement (annual, 2023-12-31) — Diluted Average Shares: 1528210.00
XBIO income_statement (annual, 2023-12-31) — Diluted EPS: -2.71
XBIO income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -4134578.00
XBIO income_statement (annual, 2023-12-31) — EBIT: -4515715.00
XBIO income_statement (annual, 2023-12-31) — EBITDA: -4515715.00
XBIO cash_flow (annual, 2023-12-31) — End Cash Position: 8983046.00
XBIO cash_flow (annual, 2023-12-31) — Free Cash Flow: -4114219.00
XBIO balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: 253734.00
XBIO income_statement (annual, 2023-12-31) — General And Administrative Expense: 3560936.00
XBIO income_statement (annual, 2023-12-31) — Interest Income: 355757.00
XBIO income_statement (annual, 2023-12-31) — Interest Income Non Operating: 355757.00
XBIO cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 0.00
XBIO balance_sheet (annual, 2023-12-31) — Invested Capital: 9793837.00
XBIO cash_flow (annual, 2023-12-31) — Investing Cash Flow: 0.00
XBIO income_statement (annual, 2023-12-31) — Net Income: -4134578.00
XBIO income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -4134578.00
XBIO income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -4134578.00
XBIO income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -4134578.00
XBIO income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -4134578.00
XBIO cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -4134578.00
XBIO income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -4134578.00
XBIO cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: 0.00
XBIO income_statement (annual, 2023-12-31) — Net Interest Income: 355757.00
XBIO income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 355757.00
XBIO balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 9795641.00
XBIO income_statement (annual, 2023-12-31) — Normalized EBITDA: -4515715.00
XBIO income_statement (annual, 2023-12-31) — Normalized Income: -4134578.00
XBIO cash_flow (annual, 2023-12-31) — Operating Cash Flow: -4114219.00
XBIO income_statement (annual, 2023-12-31) — Operating Income: -4515715.00
XBIO income_statement (annual, 2023-12-31) — Operating Revenue: 2539986.00
XBIO balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 1540684.00
XBIO balance_sheet (annual, 2023-12-31) — Other Current Assets: 603828.00
XBIO balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 48256.00
XBIO balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: 253734.00
XBIO income_statement (annual, 2023-12-31) — Other Gand A: 3560936.00
XBIO income_statement (annual, 2023-12-31) — Other Income Expense: 25380.00
XBIO balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 1018352.00
XBIO income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 25380.00
XBIO balance_sheet (annual, 2023-12-31) — Payables: 240832.00
XBIO balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 761329.00
XBIO balance_sheet (annual, 2023-12-31) — Preferred Stock: 1804.00
XBIO balance_sheet (annual, 2023-12-31) — Preferred Stock Equity: 1804.00
XBIO income_statement (annual, 2023-12-31) — Pretax Income: -4134578.00
XBIO cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: 0.00
XBIO income_statement (annual, 2023-12-31) — Reconciled Depreciation: 0.00
XBIO income_statement (annual, 2023-12-31) — Research And Development: 3494765.00
XBIO balance_sheet (annual, 2023-12-31) — Retained Earnings: -193234196.00
XBIO income_statement (annual, 2023-12-31) — Selling General And Administration: 3560936.00
XBIO balance_sheet (annual, 2023-12-31) — Share Issued: 1543385.00
XBIO cash_flow (annual, 2023-12-31) — Stock Based Compensation: 283085.00
XBIO balance_sheet (annual, 2023-12-31) — Stockholders Equity: 9795641.00
XBIO balance_sheet (annual, 2023-12-31) — Tangible Book Value: 9793837.00
XBIO income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
XBIO income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.00
XBIO balance_sheet (annual, 2023-12-31) — Total Assets: 10605226.00
XBIO balance_sheet (annual, 2023-12-31) — Total Capitalization: 9795641.00
XBIO balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 9795641.00
XBIO income_statement (annual, 2023-12-31) — Total Expenses: 7055701.00
XBIO balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 809585.00
XBIO balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 1018352.00
XBIO balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
XBIO income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -4515715.00
XBIO balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 2701.00
XBIO balance_sheet (annual, 2023-12-31) — Treasury Stock: 5281180.00
XBIO balance_sheet (annual, 2023-12-31) — Working Capital: 8777289.00
XBIO income_statement (quarterly, 2024-09-30) — Basic Average Shares: 1541722.00
XBIO income_statement (quarterly, 2024-09-30) — Basic EPS: -0.28
XBIO cash_flow (quarterly, 2024-09-30) — Change In Other Current Assets: 0.00
XBIO income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 1541722.00
XBIO income_statement (quarterly, 2024-09-30) — Diluted EPS: -0.28
XBIO balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 1018352.00
XBIO income_statement (annual, 2024-12-31) — +Operating Expense: 6704712.00
XBIO income_statement (annual, 2024-12-31) — +Total Revenue: 2500284.00
XBIO balance_sheet (annual, 2024-12-31) — Accounts Payable: 283615.00
XBIO balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 208225748.00
XBIO income_statement (annual, 2024-12-31) — Basic Average Shares: 1541339.00
XBIO income_statement (annual, 2024-12-31) — Basic EPS: -2.57
XBIO cash_flow (annual, 2024-12-31) — Beginning Cash Position: 8983046.00
XBIO balance_sheet (annual, 2024-12-31) — Capital Stock: 3349.00
XBIO balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 6165568.00
XBIO balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 6165568.00
XBIO balance_sheet (annual, 2024-12-31) — Cash Financial: 6165568.00
XBIO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 1.00
XBIO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -2817478.00
XBIO cash_flow (annual, 2024-12-31) — Change In Account Payable: 84678.00
XBIO cash_flow (annual, 2024-12-31) — Change In Other Current Assets: 704431.00
XBIO cash_flow (quarterly, 2024-12-31) — Change In Other Current Assets: 704431.00
XBIO cash_flow (annual, 2024-12-31) — Change In Payable: 84678.00
XBIO cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 84678.00
XBIO cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 181874.00
XBIO cash_flow (annual, 2024-12-31) — Change In Working Capital: 970983.00
XBIO cash_flow (annual, 2024-12-31) — Changes In Cash: -2817478.00
XBIO balance_sheet (annual, 2024-12-31) — Common Stock: 1545.00
XBIO balance_sheet (annual, 2024-12-31) — Common Stock Equity: 6005376.00
XBIO cash_flow (annual, 2024-12-31) — Common Stock Issuance: 1.00
XBIO balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 576445.00
XBIO balance_sheet (annual, 2024-12-31) — Current Assets: 6587522.00
XBIO balance_sheet (annual, 2024-12-31) — Current Liabilities: 894263.00
XBIO income_statement (annual, 2024-12-31) — Diluted Average Shares: 1541339.00
XBIO income_statement (annual, 2024-12-31) — Diluted EPS: -2.57
XBIO income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -3960275.00
XBIO income_statement (annual, 2024-12-31) — EBIT: -4204428.00
XBIO income_statement (annual, 2024-12-31) — EBITDA: -4204428.00
XBIO cash_flow (annual, 2024-12-31) — End Cash Position: 6165568.00
XBIO cash_flow (annual, 2024-12-31) — Financing Cash Flow: 0.00
XBIO cash_flow (annual, 2024-12-31) — Free Cash Flow: -2817478.00
XBIO balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 253734.00
XBIO income_statement (annual, 2024-12-31) — General And Administrative Expense: 3416380.00
XBIO income_statement (annual, 2024-12-31) — Interest Income: 249861.00
XBIO income_statement (annual, 2024-12-31) — Interest Income Non Operating: 249861.00
XBIO cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 0.00
XBIO balance_sheet (annual, 2024-12-31) — Invested Capital: 6005376.00
XBIO cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 1.00
XBIO cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 1.00
XBIO income_statement (annual, 2024-12-31) — Net Income: -3960275.00
XBIO income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -3960275.00
XBIO income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -3960275.00
XBIO income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -3960275.00
XBIO income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -3960275.00
XBIO cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -3960275.00
XBIO income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -3960275.00
XBIO income_statement (annual, 2024-12-31) — Net Interest Income: 249861.00
XBIO income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 249861.00
XBIO cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -1.00
XBIO balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 6007180.00
XBIO income_statement (annual, 2024-12-31) — Normalized EBITDA: -4204428.00
XBIO income_statement (annual, 2024-12-31) — Normalized Income: -3960275.00
XBIO cash_flow (annual, 2024-12-31) — Operating Cash Flow: -2817478.00
XBIO income_statement (annual, 2024-12-31) — Operating Income: -4204428.00
XBIO income_statement (annual, 2024-12-31) — Operating Revenue: 2500284.00
XBIO balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 1542139.00
XBIO balance_sheet (annual, 2024-12-31) — Other Current Assets: 421954.00
XBIO balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 34203.00
XBIO balance_sheet (quarterly, 2024-12-31) — Other Current Liabilities: 34203.00
XBIO balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: 253734.00
XBIO income_statement (annual, 2024-12-31) — Other Gand A: 3416380.00
XBIO income_statement (annual, 2024-12-31) — Other Income Expense: -5708.00
XBIO balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 313921.00
XBIO balance_sheet (quarterly, 2024-12-31) — Other Non Current Assets: 313921.00
XBIO income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: -5708.00
XBIO balance_sheet (annual, 2024-12-31) — Payables: 283615.00
XBIO balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 860060.00
XBIO balance_sheet (annual, 2024-12-31) — Preferred Stock: 1804.00
XBIO balance_sheet (annual, 2024-12-31) — Preferred Stock Equity: 1804.00
XBIO income_statement (annual, 2024-12-31) — Pretax Income: -3960275.00
XBIO income_statement (annual, 2024-12-31) — Research And Development: 3288332.00
XBIO balance_sheet (annual, 2024-12-31) — Retained Earnings: -197194471.00
XBIO income_statement (annual, 2024-12-31) — Selling General And Administration: 3416380.00
XBIO balance_sheet (annual, 2024-12-31) — Share Issued: 1544840.00
XBIO cash_flow (annual, 2024-12-31) — Stock Based Compensation: 171814.00
XBIO balance_sheet (annual, 2024-12-31) — Stockholders Equity: 6007180.00
XBIO balance_sheet (annual, 2024-12-31) — Tangible Book Value: 6005376.00
XBIO income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
XBIO income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.00
XBIO balance_sheet (annual, 2024-12-31) — Total Assets: 6901443.00
XBIO balance_sheet (annual, 2024-12-31) — Total Capitalization: 6007180.00
XBIO balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 6007180.00
XBIO income_statement (annual, 2024-12-31) — Total Expenses: 6704712.00
XBIO balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 894263.00
XBIO balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 313921.00
XBIO balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
XBIO income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -4204428.00
XBIO balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 2701.00
XBIO balance_sheet (annual, 2024-12-31) — Treasury Stock: 5281180.00
XBIO balance_sheet (annual, 2024-12-31) — Working Capital: 5693259.00
XBIO income_statement (quarterly, 2025-03-31) — +Operating Expense: 1535670.00
XBIO income_statement (quarterly, 2025-03-31) — +Total Revenue: 593261.00
XBIO balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 240293.00
XBIO balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 208244999.00
XBIO income_statement (quarterly, 2025-03-31) — Basic Average Shares: 1542139.00
XBIO income_statement (quarterly, 2025-03-31) — Basic EPS: -0.59
XBIO cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 6165568.00
XBIO balance_sheet (quarterly, 2025-03-31) — Capital Stock: 3349.00
XBIO balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 5163676.00
XBIO balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 5163676.00
XBIO balance_sheet (quarterly, 2025-03-31) — Cash Financial: 5163676.00
XBIO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -1001892.00
XBIO cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -226336.00
XBIO cash_flow (quarterly, 2025-03-31) — Change In Payable: -226336.00
XBIO cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -226336.00
XBIO cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 108334.00
XBIO cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -118002.00
XBIO cash_flow (quarterly, 2025-03-31) — Changes In Cash: -1001892.00
XBIO balance_sheet (quarterly, 2025-03-31) — Common Stock: 1545.00
XBIO balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 5121486.00
XBIO balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 427634.00
XBIO balance_sheet (quarterly, 2025-03-31) — Current Assets: 5477296.00
XBIO balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 667927.00
XBIO income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 1542139.00
XBIO income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.59
XBIO income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -903141.00
XBIO income_statement (quarterly, 2025-03-31) — EBIT: -942409.00
XBIO income_statement (quarterly, 2025-03-31) — EBITDA: -942409.00
XBIO cash_flow (quarterly, 2025-03-31) — End Cash Position: 5163676.00
XBIO cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -1001892.00
XBIO balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 253734.00
XBIO income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 656641.00
XBIO income_statement (quarterly, 2025-03-31) — Interest Income: 39190.00
XBIO income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 39190.00
XBIO cash_flow (quarterly, 2025-03-31) — Interest Paid Supplemental Data: 0.00
XBIO balance_sheet (quarterly, 2025-03-31) — Invested Capital: 5121486.00
XBIO income_statement (quarterly, 2025-03-31) — Net Income: -903141.00
XBIO income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -903141.00
XBIO income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -903141.00
XBIO income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -903141.00
XBIO income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -903141.00
XBIO cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -903141.00
XBIO income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -903141.00
XBIO income_statement (quarterly, 2025-03-31) — Net Interest Income: 39190.00
XBIO income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 39190.00
XBIO balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 5123290.00
XBIO income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -942409.00
XBIO income_statement (quarterly, 2025-03-31) — Normalized Income: -903141.00
XBIO cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -1001892.00
XBIO income_statement (quarterly, 2025-03-31) — Operating Income: -942409.00
XBIO income_statement (quarterly, 2025-03-31) — Operating Revenue: 593261.00
XBIO balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 1542139.00
XBIO balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 313620.00
XBIO balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: 253734.00
XBIO income_statement (quarterly, 2025-03-31) — Other Gand A: 656641.00
XBIO income_statement (quarterly, 2025-03-31) — Other Income Expense: 78.00
XBIO balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 313921.00
XBIO income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 78.00
XBIO balance_sheet (quarterly, 2025-03-31) — Payables: 240293.00
XBIO balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 667927.00
XBIO balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 1804.00
XBIO balance_sheet (quarterly, 2025-03-31) — Preferred Stock Equity: 1804.00
XBIO income_statement (quarterly, 2025-03-31) — Pretax Income: -903141.00
XBIO income_statement (quarterly, 2025-03-31) — Research And Development: 879029.00
XBIO balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -198097612.00
XBIO income_statement (quarterly, 2025-03-31) — Selling General And Administration: 656641.00
XBIO balance_sheet (quarterly, 2025-03-31) — Share Issued: 1544840.00
XBIO cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 19251.00
XBIO balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 5123290.00
XBIO balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 5121486.00
XBIO income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
XBIO income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
XBIO balance_sheet (quarterly, 2025-03-31) — Total Assets: 5791217.00
XBIO balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 5123290.00
XBIO balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 5123290.00
XBIO income_statement (quarterly, 2025-03-31) — Total Expenses: 1535670.00
XBIO balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 667927.00
XBIO balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 313921.00
XBIO balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 0.00
XBIO income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -942409.00
XBIO balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 2701.00
XBIO balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 5281180.00
XBIO balance_sheet (quarterly, 2025-03-31) — Working Capital: 4809369.00
XBIO income_statement (quarterly, 2025-06-30) — +Operating Expense: 1314309.00
XBIO income_statement (quarterly, 2025-06-30) — +Total Revenue: 589897.00
XBIO balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 346828.00
XBIO balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 208260682.00
XBIO income_statement (quarterly, 2025-06-30) — Basic Average Shares: 1542139.00
XBIO income_statement (quarterly, 2025-06-30) — Basic EPS: -0.45
XBIO cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 5163676.00
XBIO balance_sheet (quarterly, 2025-06-30) — Capital Stock: 3349.00
XBIO balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 4779846.00
XBIO balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 4779846.00
XBIO balance_sheet (quarterly, 2025-06-30) — Cash Financial: 4779846.00
XBIO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -383830.00
XBIO cash_flow (quarterly, 2025-06-30) — Change In Account Payable: 235503.00
XBIO cash_flow (quarterly, 2025-06-30) — Change In Payable: 235503.00
XBIO cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 235503.00
XBIO cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -260234.00
XBIO cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 289190.00
XBIO cash_flow (quarterly, 2025-06-30) — Changes In Cash: -383830.00
XBIO balance_sheet (quarterly, 2025-06-30) — Common Stock: 1545.00
XBIO balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 4448466.00
XBIO balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 556602.00
XBIO balance_sheet (quarterly, 2025-06-30) — Current Assets: 5353700.00
XBIO balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 903430.00
XBIO income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 1542139.00
XBIO income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.45
XBIO income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -688703.00
XBIO income_statement (quarterly, 2025-06-30) — EBIT: -724412.00
XBIO income_statement (quarterly, 2025-06-30) — EBITDA: -724412.00
XBIO cash_flow (quarterly, 2025-06-30) — End Cash Position: 4779846.00
XBIO cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -383830.00
XBIO balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 253734.00
XBIO income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 657752.00
XBIO income_statement (quarterly, 2025-06-30) — Interest Income: 34232.00
XBIO income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 34232.00
XBIO cash_flow (quarterly, 2025-06-30) — Interest Paid Supplemental Data: 0.00
XBIO balance_sheet (quarterly, 2025-06-30) — Invested Capital: 4448466.00
XBIO income_statement (quarterly, 2025-06-30) — Net Income: -688703.00
XBIO income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -688703.00
XBIO income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -688703.00
XBIO income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -688703.00
XBIO income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -688703.00
XBIO cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -688703.00
XBIO income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -688703.00
XBIO income_statement (quarterly, 2025-06-30) — Net Interest Income: 34232.00
XBIO income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 34232.00
XBIO balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 4450270.00
XBIO income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -724412.00
XBIO income_statement (quarterly, 2025-06-30) — Normalized Income: -688703.00
XBIO cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -383830.00
XBIO income_statement (quarterly, 2025-06-30) — Operating Income: -724412.00
XBIO income_statement (quarterly, 2025-06-30) — Operating Revenue: 589897.00
XBIO balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 1542139.00
XBIO balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 573854.00
XBIO balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: 253734.00
XBIO income_statement (quarterly, 2025-06-30) — Other Gand A: 657752.00
XBIO income_statement (quarterly, 2025-06-30) — Other Income Expense: 1477.00
XBIO income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 1477.00
XBIO balance_sheet (quarterly, 2025-06-30) — Payables: 346828.00
XBIO balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 903430.00
XBIO balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 1804.00
XBIO balance_sheet (quarterly, 2025-06-30) — Preferred Stock Equity: 1804.00
XBIO income_statement (quarterly, 2025-06-30) — Pretax Income: -688703.00
XBIO income_statement (quarterly, 2025-06-30) — Research And Development: 656557.00
XBIO balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -198786315.00
XBIO income_statement (quarterly, 2025-06-30) — Selling General And Administration: 657752.00
XBIO balance_sheet (quarterly, 2025-06-30) — Share Issued: 1544840.00
XBIO cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 15683.00
XBIO balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 4450270.00
XBIO balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 4448466.00
XBIO income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
XBIO income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
XBIO balance_sheet (quarterly, 2025-06-30) — Total Assets: 5353700.00
XBIO balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 4450270.00
XBIO balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 4450270.00
XBIO income_statement (quarterly, 2025-06-30) — Total Expenses: 1314309.00
XBIO balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 903430.00
XBIO balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 0.00
XBIO balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 0.00
XBIO income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -724412.00
XBIO balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 2701.00
XBIO balance_sheet (quarterly, 2025-06-30) — Treasury Stock: 5281180.00
XBIO balance_sheet (quarterly, 2025-06-30) — Working Capital: 4450270.00
XBIO income_statement (quarterly, 2025-09-30) — +Operating Expense: 1571691.00
XBIO income_statement (quarterly, 2025-09-30) — +Total Revenue: 1026957.00
XBIO balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 578250.00
XBIO balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 208276537.00
XBIO income_statement (quarterly, 2025-09-30) — Basic Average Shares: 1542139.00
XBIO income_statement (quarterly, 2025-09-30) — Basic EPS: -0.33
XBIO cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 4779846.00
XBIO balance_sheet (quarterly, 2025-09-30) — Capital Stock: 3349.00
XBIO balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 4121599.00
XBIO balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 4121599.00
XBIO balance_sheet (quarterly, 2025-09-30) — Cash Financial: 4121599.00
XBIO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -658247.00
XBIO cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 208345.00
XBIO cash_flow (quarterly, 2025-09-30) — Change In Other Current Assets: 0.00
XBIO cash_flow (quarterly, 2025-09-30) — Change In Payable: 208345.00
XBIO cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 208345.00
XBIO cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -372507.00
XBIO cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -164162.00
XBIO cash_flow (quarterly, 2025-09-30) — Changes In Cash: -658247.00
XBIO balance_sheet (quarterly, 2025-09-30) — Common Stock: 1545.00
XBIO balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 3954381.00
XBIO balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 533525.00
XBIO balance_sheet (quarterly, 2025-09-30) — Current Assets: 5067960.00
XBIO balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 1111775.00
XBIO income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 1542139.00
XBIO income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.33
XBIO income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -509940.00
XBIO income_statement (quarterly, 2025-09-30) — EBIT: -544734.00
XBIO income_statement (quarterly, 2025-09-30) — EBITDA: -544734.00
XBIO cash_flow (quarterly, 2025-09-30) — End Cash Position: 4121599.00
XBIO cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -658247.00
XBIO balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 253734.00
XBIO income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 815209.00
XBIO income_statement (quarterly, 2025-09-30) — Interest Income: 30783.00
XBIO income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 30783.00
XBIO cash_flow (quarterly, 2025-09-30) — Interest Paid Supplemental Data: 0.00
XBIO balance_sheet (quarterly, 2025-09-30) — Invested Capital: 3954381.00
XBIO income_statement (quarterly, 2025-09-30) — Net Income: -509940.00
XBIO income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -509940.00
XBIO income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -509940.00
XBIO income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -509940.00
XBIO income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -509940.00
XBIO cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -509940.00
XBIO income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -509940.00
XBIO income_statement (quarterly, 2025-09-30) — Net Interest Income: 30783.00
XBIO income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 30783.00
XBIO balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 3956185.00
XBIO income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -544734.00
XBIO income_statement (quarterly, 2025-09-30) — Normalized Income: -509940.00
XBIO cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -658247.00
XBIO income_statement (quarterly, 2025-09-30) — Operating Income: -544734.00
XBIO income_statement (quarterly, 2025-09-30) — Operating Revenue: 1026957.00
XBIO balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 1542139.00
XBIO balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 946361.00
XBIO balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 253734.00
XBIO income_statement (quarterly, 2025-09-30) — Other Gand A: 815209.00
XBIO income_statement (quarterly, 2025-09-30) — Other Income Expense: 4011.00
XBIO income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 4011.00
XBIO balance_sheet (quarterly, 2025-09-30) — Payables: 578250.00
XBIO balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 1111775.00
XBIO balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 1804.00
XBIO balance_sheet (quarterly, 2025-09-30) — Preferred Stock Equity: 1804.00
XBIO income_statement (quarterly, 2025-09-30) — Pretax Income: -509940.00
XBIO income_statement (quarterly, 2025-09-30) — Research And Development: 756482.00
XBIO balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -199296255.00
XBIO income_statement (quarterly, 2025-09-30) — Selling General And Administration: 815209.00
XBIO balance_sheet (quarterly, 2025-09-30) — Share Issued: 1544840.00
XBIO cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 15855.00
XBIO balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 3956185.00
XBIO balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 3954381.00
XBIO income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
XBIO income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
XBIO balance_sheet (quarterly, 2025-09-30) — Total Assets: 5067960.00
XBIO balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 3956185.00
XBIO balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 3956185.00
XBIO income_statement (quarterly, 2025-09-30) — Total Expenses: 1571691.00
XBIO balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 1111775.00
XBIO balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 0.00
XBIO balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 0.00
XBIO income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -544734.00
XBIO balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 2701.00
XBIO balance_sheet (quarterly, 2025-09-30) — Treasury Stock: 5281180.00
XBIO balance_sheet (quarterly, 2025-09-30) — Working Capital: 3956185.00
XBIO income_statement (annual, 2025-12-31) — +Operating Expense: 5810993.00
XBIO income_statement (quarterly, 2025-12-31) — +Operating Expense: 1389323.00
XBIO income_statement (annual, 2025-12-31) — +Total Revenue: 2976411.00
XBIO income_statement (quarterly, 2025-12-31) — +Total Revenue: 766296.00
XBIO balance_sheet (annual, 2025-12-31) — Accounts Payable: 258109.00
XBIO balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 258109.00
XBIO balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 212294851.00
XBIO balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 212294851.00
XBIO income_statement (annual, 2025-12-31) — Basic Average Shares: 1701571.00
XBIO income_statement (annual, 2025-12-31) — Basic EPS: -1.58
XBIO cash_flow (annual, 2025-12-31) — Beginning Cash Position: 6165568.00
XBIO cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 4121599.00
XBIO balance_sheet (annual, 2025-12-31) — Capital Stock: 3748.00
XBIO balance_sheet (quarterly, 2025-12-31) — Capital Stock: 3748.00
XBIO balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 7883632.00
XBIO balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 7883632.00
XBIO balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 7883632.00
XBIO balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 7883632.00
XBIO balance_sheet (annual, 2025-12-31) — Cash Financial: 7883632.00
XBIO balance_sheet (quarterly, 2025-12-31) — Cash Financial: 7883632.00
XBIO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 4004715.00
XBIO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -2286651.00
XBIO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -242682.00
XBIO cash_flow (annual, 2025-12-31) — Change In Account Payable: 73762.00
XBIO cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -143750.00
XBIO cash_flow (annual, 2025-12-31) — Change In Other Current Assets: 0.00
XBIO cash_flow (quarterly, 2025-12-31) — Change In Other Current Assets: -313921.00
XBIO cash_flow (annual, 2025-12-31) — Change In Payable: 73762.00
XBIO cash_flow (quarterly, 2025-12-31) — Change In Payable: -143750.00
XBIO cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 73762.00
XBIO cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -143750.00
XBIO cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: 255660.00
XBIO cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 780067.00
XBIO cash_flow (annual, 2025-12-31) — Change In Working Capital: 329422.00
XBIO cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 322396.00
XBIO cash_flow (annual, 2025-12-31) — Changes In Cash: 1718064.00
XBIO cash_flow (quarterly, 2025-12-31) — Changes In Cash: 3762033.00
XBIO balance_sheet (annual, 2025-12-31) — Common Stock: 2294.00
XBIO balance_sheet (quarterly, 2025-12-31) — Common Stock: 2294.00
XBIO balance_sheet (annual, 2025-12-31) — Common Stock Equity: 7394368.00
XBIO balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 7394368.00
XBIO cash_flow (annual, 2025-12-31) — Common Stock Issuance: 4004715.00
XBIO balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 686041.00
XBIO balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 686041.00
XBIO balance_sheet (annual, 2025-12-31) — Current Assets: 8049926.00
XBIO balance_sheet (quarterly, 2025-12-31) — Current Assets: 8049926.00
XBIO balance_sheet (annual, 2025-12-31) — Current Liabilities: 968025.00
XBIO balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 968025.00
XBIO income_statement (annual, 2025-12-31) — Diluted Average Shares: 1701571.00
XBIO income_statement (annual, 2025-12-31) — Diluted EPS: -1.58
XBIO income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -2680860.00
XBIO income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -579076.00
XBIO income_statement (annual, 2025-12-31) — EBIT: -2834582.00
XBIO income_statement (quarterly, 2025-12-31) — EBIT: -623027.00
XBIO income_statement (annual, 2025-12-31) — EBITDA: -2834582.00
XBIO income_statement (quarterly, 2025-12-31) — EBITDA: -623027.00
XBIO cash_flow (annual, 2025-12-31) — End Cash Position: 7883632.00
XBIO cash_flow (quarterly, 2025-12-31) — End Cash Position: 7883632.00
XBIO cash_flow (annual, 2025-12-31) — Financing Cash Flow: 4004715.00
XBIO cash_flow (annual, 2025-12-31) — Free Cash Flow: -2286651.00
XBIO cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -242682.00
XBIO balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 253734.00
XBIO balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 253734.00
XBIO income_statement (annual, 2025-12-31) — General And Administrative Expense: 2745509.00
XBIO income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 615907.00
XBIO income_statement (annual, 2025-12-31) — Interest Income: 147997.00
XBIO income_statement (quarterly, 2025-12-31) — Interest Income: 43792.00
XBIO income_statement (annual, 2025-12-31) — Interest Income Non Operating: 147997.00
XBIO income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 43792.00
XBIO cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 0.00
XBIO cash_flow (quarterly, 2025-12-31) — Interest Paid Supplemental Data: 0.00
XBIO balance_sheet (annual, 2025-12-31) — Invested Capital: 7394368.00
XBIO balance_sheet (quarterly, 2025-12-31) — Invested Capital: 7394368.00
XBIO cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 4004715.00
XBIO cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 4004715.00
XBIO income_statement (annual, 2025-12-31) — Net Income: -2680860.00
XBIO income_statement (quarterly, 2025-12-31) — Net Income: -579076.00
XBIO income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -2680860.00
XBIO income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -579076.00
XBIO income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -2680860.00
XBIO income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -579076.00
XBIO income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -2680860.00
XBIO income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -579076.00
XBIO income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -2680860.00
XBIO income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -579076.00
XBIO cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -2680860.00
XBIO cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -579076.00
XBIO income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -2680860.00
XBIO income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -579076.00
XBIO income_statement (annual, 2025-12-31) — Net Interest Income: 147997.00
XBIO income_statement (quarterly, 2025-12-31) — Net Interest Income: 43792.00
XBIO income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 147997.00
XBIO income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 43792.00
XBIO balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 7395822.00
XBIO balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 7395822.00
XBIO income_statement (annual, 2025-12-31) — Normalized EBITDA: -2834582.00
XBIO income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -623027.00
XBIO income_statement (annual, 2025-12-31) — Normalized Income: -2680860.00
XBIO income_statement (quarterly, 2025-12-31) — Normalized Income: -579076.00
XBIO cash_flow (annual, 2025-12-31) — Operating Cash Flow: -2286651.00
XBIO cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -242682.00
XBIO income_statement (annual, 2025-12-31) — Operating Income: -2834582.00
XBIO income_statement (quarterly, 2025-12-31) — Operating Income: -623027.00
XBIO income_statement (annual, 2025-12-31) — Operating Revenue: 2976411.00
XBIO income_statement (quarterly, 2025-12-31) — Operating Revenue: 766296.00
XBIO balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 2291056.00
XBIO balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 2291056.00
XBIO balance_sheet (annual, 2025-12-31) — Other Current Assets: 166294.00
XBIO balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 166294.00
XBIO balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 23875.00
XBIO balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 23875.00
XBIO balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: 253734.00
XBIO balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 253734.00
XBIO income_statement (annual, 2025-12-31) — Other Gand A: 2745509.00
XBIO income_statement (quarterly, 2025-12-31) — Other Gand A: 615907.00
XBIO income_statement (annual, 2025-12-31) — Other Income Expense: 5725.00
XBIO income_statement (quarterly, 2025-12-31) — Other Income Expense: 159.00
XBIO balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 313921.00
XBIO balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 313921.00
XBIO income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 5725.00
XBIO income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 159.00
XBIO balance_sheet (annual, 2025-12-31) — Payables: 258109.00
XBIO balance_sheet (quarterly, 2025-12-31) — Payables: 258109.00
XBIO balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 944150.00
XBIO balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 944150.00
XBIO balance_sheet (annual, 2025-12-31) — Preferred Stock: 1454.00
XBIO balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 1454.00
XBIO balance_sheet (annual, 2025-12-31) — Preferred Stock Equity: 1454.00
XBIO balance_sheet (quarterly, 2025-12-31) — Preferred Stock Equity: 1454.00
XBIO income_statement (annual, 2025-12-31) — Pretax Income: -2680860.00
XBIO income_statement (quarterly, 2025-12-31) — Pretax Income: -579076.00
XBIO income_statement (annual, 2025-12-31) — Research And Development: 3065484.00
XBIO income_statement (quarterly, 2025-12-31) — Research And Development: 773416.00
XBIO balance_sheet (annual, 2025-12-31) — Retained Earnings: -199875331.00